IRS Logo
Print - Click this link to Print this page

Qualifying Therapeutic Discovery Project Grants for the State of New Jersey

The listings below represent the applicants that have been awarded a Qualifying Therapeutic Discovery Program Grant.

The project descriptions below were extracted from the applicant certification forms as submitted.

New Jersey $ 51,109,445.09
Applicant Name Project Name Grants Awarded for 2009 Grants Awarded for 2010
3D Biotek, LLC Bioabsorbable drug-eluting stents $ 14,397.32 $ 117,737.43
Actinium Pharmaceuticals, Inc Alpha Particle Immunotherapy (APIT) drugs development $ 244,479.24  
AD4-PHARMA STABILIZATION OF EGFR CLOSED FORM USING SMALL MOLECULE COMPOUNDS $ 238,708.50 $ 5,770.75
AD4-Pharma Small molecule compounds that mimic ERBITUX binding $ 238,708.50 $ 5,770.75
AD4-PHARMA MDM2 INHIBITORS IN COMBINATION WITH EGFR KINASE INHIBITORS $ 119,353.50 $ 108,498.00
ADMA Biologics Resplmmune™ for the treatment of Respiratory Syncytial Virus $ 244,479.25  
Advanced Technologies for Novel Therapeutics, LLC Preclinical and clinical development of a novel and potent anti-cancer therapeutics $ 191,650.00 $ 52,829.25
Advaxis Inc ADXS11-001, a live attenuated bacterial vaccine for the treatment of cancer $ 244,479.24  
Aegerion Pharmaceuticals, Inc Aegerion Pharaceuticals, Inc Iomitapide development program $ 244,479.25  
Aerie Pharmaceuticals Inc AR-12286 $ 244,479.24  
Aestus Therapeutics, Inc Treating neuropathic pain by means of novel mechanisms   $ 244,479.24
Agennix USA, Inc RGB-286638 $ 244,479.25  
Agile Therapeutics, Inc. Agile Therapeutics' Skinfusion - Low Dose Contraceptive Patch $ 244,479.25  
Alitair Pharmaceuticals Inc DBA The cough Company Method for reducing or preventing overdose events with pharmaceuticals   $ 244,479.24
Amicus  Therapeutics,Inc. Early Onset Familial Alzheimers Disease $ 175,445.00 $ 69,034.25
Amicus Therapeutics Inc Sporadic Alzheimer's Disease $ 244,479.25  
Amicus Therapeutics, Inc AT1001 for Fabry Disease $ 244,479.25  
Amicus Therapeutics, Inc AT1001 in Combination with Enzyme Replacement Therapy for Fabry Disease $ 244,479.25  
Amicus Therapeutics, Inc Alpha-One Antitrypsin Deficiency $ 244,479.25  
Amicus Therapeutics,Inc. Pharmacological Chaperones for Parkinson's Disease $ 244,479.25  
AMORCYTE INC AMR-001 Phase 2 Trial $ 244,479.25  
Angel Medical Systems Inc Nextgen R & D Project $ 244,479.24  
Angel Medical Systems, Inc Alerts R&D Project $ 244,479.24  
Antyra Inc Treatment of Cancer with a novel IGF-1R antagonist, ANT-429 $ 204,273.00 $ 40,206.24
Arno Therapeutics Inc Dev of AR-67: A Novel, Third-generation Comptothecin Analogue for the Treatment of Cancer $ 244,479.24  
Arno Therapeutics Inc Development of AR-42: A Novel, pan-DAC Inhibitor for the Treatment of Cancer $ 244,479.24  
Arno Therapeutics, Inc. Dev. Of AR-12: A Novel and Potentially First-in-class Agent for the Treatment of Cancer $ 244,479.24  
BeFree! LLC BeFree! $ 1,453.43 $ 26,782.00
Bioscience Development Inc Diagnostic Test for Lyme & Tick-borne Diseases   $ 244,479.24
Bioscience Development Inc Vaccines and diagnostic tests for Burkholderia Infections $ 57,899.00 $ 186,580.24
Bright Cloud International Arm Motor Rehabilitation, Entertainment and Cognition System for the Elderly   $ 32,143.00
Cahaba Pharmaceuticals, Inc. TCN-P (triciribine phosphate) Cancer Treatment   $ 244,479.25
Cahaba Pharmaceuticals, Inc. 1UO (.1% uracil topical) DPD Inhibitor $ 244,479.25  
Cancer Genetics, Inc. MatBA $ 244,479.25  
Cancer Genetics, Inc. FISH-based HPV-associated Cancer Test (FHACT) $ 209,466.50 $ 35,012.75
Cancer Genetics, Inc. FISH-based Renal Cancer Diagnostics (FReCAD) $ 125,680.50 $ 118,798.75
Celator Pharmaceuticals, Inc CPX-351 (Cytarabine:Daunorubicin) Liposome Injection $ 244,479.25  
Chemo Dynamics Inc A Drug Discovery Program Based on Metalloporphyrin with Peptide end links $ 42,222.00 $ 46,250.00
Chromocell Corporation Development of novel, selective NaV1.7 antagonists for treatment of chronic pain $ 244,479.25  
ChromoDynamics Novel PAP assay with automated hyperspectral imaging slide reader $ 177,631.12 $ 66,848.12
Circulite Inc. Circulite Synergy Endovascular System $ 244,479.25  
Circulite Inc. Circulite Synergy Surgical System $ 244,479.25  
Circuport, Inc Circuport Vacsular Access Systems for Hemodialysis $ 98,515.43 $ 145,963.82
Columbia Laboratories, Inc Evaluate CRINONE ®/ PROCHIEVE ® for Reduction of Preterm Births in Women $ 244,479.24  
CorMedix Inc Deferiprone $ 244,479.25  
CorMedix Inc Neutrolin $ 244,479.25  
Cornerstone Pharmaceuticals Inc Development project of Emulsiphan Platform (EmPA) $ 121,668.91 $ 122,810.34
Cornerstone Pharmaceuticals, Inc. AEMD $ 244,479.25  
CytoSorbents Inc EntericSorb Anti-inflammatory therapy for life-threatening disease   $ 244,479.25
CytoSorbents Inc CytoSorb Autologous Blood Transfusion $ 244,479.25  
Derma Sciences Inc DSC 127 Clinical Development Program $ 244,479.25  
DiamiR, LLC Development of ASDmiR, molecular test for early detection and monitoring of Alzheimer's Disease.   $ 156,600.00
Drais Pharmaceuticals, Inc. DTS-108 anti-cancer chemotherapy drug $ 244,479.24  
E2 The EndoTube Duodenal Drug Delivery Reservoir $ 25,000.00 $ 35,000.00
E2, LLC The EndoSleeve Project $ 244,479.25  
Eagle Pharmaceuticals, Inc. Ready-to-Use Oncology Product "P" $ 20,500.00 $ 114,501.00
Eagle Pharmaceuticals, Inc. Diluent for Oncology Product "A" $ 244,479.25  
Eagle Pharmaceuticals, Inc. Nanosuspension for Treatment of Malignant Hyperthermia $ 244,479.25  
Eagle Pharmaceuticals, Inc. Diluent for Oncology Product "D" $ 244,479.25  
Eagle Pharmaceuticals, Inc. Ready-to-use Oncology Product "B" $ 244,479.25  
EDG Therapeutics, Inc. New Drugs to treat Angiogenesis in Cancer   $ 50,000.00
Edge Therapeutics, Inc NimoGel to prevent secondary stroke (vasospasm) and improve outcome after sudden brain injury. $ 42,203.50 $ 202,275.75
Edusa Pharmaceuticals, Inc. Pumosetrag Clinical Trials $ 108,798.50 $ 135,680.75
ElectroCore LLC Resolve System for treating acute Bronchoconstriction $ 244,479.25  
ElectroCore LLC Rejuvenation System for Treating Chronic Obstructive Pulmonary Disease (COPD) $ 244,479.25  
ElectroCore LLC Revive System for treating Sepsis and Septic Shock $ 244,479.25  
ElectroCore LLC Resolution System for Treating Post-Operative Ileus $ 244,479.25  
Eleison Pharmaceuticals, Inc. Inhaled Liposomal Cisplatin for Treatment of Recurrent Pulmonary Pediatric Osteosarcoma   $ 244,479.25
Eleison Pharmaceuticals, Inc. Development of Glufosfamide for the Treatment of Second-line Pancreatic Cancer $ 29,112.50 $ 215,366.75
Elusys Therapeutics Inc. Development of a Monoclonal Antibody for Prevention and Treatment of Anthrax $ 244,479.25  
Emisphere Technologies, Inc Eligen Oral B12 $ 244,479.24  
Endovalve, Inc. Delivery System Development for Foldable Suture-free Mitral Valve Prosthesis $ 244,479.24  
Enzon Pharmaceuticals Inc Androgen Receptor (AR) Antagonist (EZN-4176) $ 244,479.24  
Enzon Pharmaceuticals, Inc HER3 Antagonist (EZN-39200) $ 78,521.50 $ 165,957.74
Enzon Pharmaceuticals, Inc PEG-SN38 $ 244,479.24  
Enzon Pharmaceuticals, Inc. Survivin Antagonist (EZN-3042) $ 244,479.24  
Enzon Pharmaceuticals, Inc. HIF-1alpha Antagonist (EZN-2968) $ 244,479.24  
EnzymeRx, LLC Pegsiticase $ 244,479.25  
Flexible Stenting Solutions, Inc Peripheral Vascular Self Expanding (SE) Stenting System (the "FlexStent") $ 244,479.24  
Follica Incorporated Drug Delivery Program for inducing Follicular Neogenesis for Scarless Wound Healing $ 237,563.01 $ 6,916.23
Follica Incorporated Clinical Program for Inducing Follicular Neogenesis for Scarless Wound Healing $ 244,147.19 $ 332.05
Galaxy Bio Inc Development of NAL 1606 as a New Delivery System for Migraine $ 146,928.00 $ 97,551.24
Genta Incorporated Tesetaxel $ 244,479.24  
Genta Incorporated Oblimersen $ 244,479.24  
HDL Therapeutics LLC Selective HDL Delipdation Therapy (Delipidation Therapy)   $ 104,429.50
Healthy Functions, LLC Pressure Ulcer Prevention and Treatment Mattress $ 15,058.00 $ 229,421.24
Healthy Functions, LLC Pressure Ulcer Prevention and Treatment Wheelchair Cushion $ 4,078.50 $ 194,000.00
HiLin Life Products, Inc KNOWHEN ® $ 87,739.50 $ 79,842.00
HMGene Inc Development of Adiptin as a Biotherapeutic to treat Obesity $ 188,500.00 $ 55,979.25
Humigen, LLC Humigen IBD1:Use of the IL-32R "Delta-9" variant to monitor prognosis and progression. $ 146,003.00 $ 98,476.24
Immunomedics Inc hLL1 Dox for multiple myeloma $ 244,479.25  
Immunomedics Inc TF4 for NHL $ 244,479.25  
Immunomedics Inc F-18 labeling technique for imaging $ 244,479.25  
Immunomedics Inc hRS7-SN-38 for lung and breast cancers. $ 244,479.24  
Immunomedics Inc Veltuzumab as a subcutaneous formulation for NHL $ 244,479.25  
Immunomedics, Inc 20-2b for NHL $ 138,342.50 $ 106,136.75
Immunomedics, Inc 22-20 for NHL $ 157,091.50 $ 87,387.75
Immunomedics, Inc hLL1 for multiple myeloma and NHL/CLL $ 244,479.25  
Immunomedics, Inc. TF2 for colorectal cancer $ 244,479.25  
Immunomedics, Inc. hPAM4 for early diagnois, imaging and therapy of pancreatic cancer $ 244,479.24  
Immunomedics, Inc. hMN14-SN-38 $ 244,479.25  
Immunomedics, Inc. IMMU-114 for B-cell lymphoma $ 41,460.50 $ 157,955.50
IntelliSante Corporation Psytracker   $ 102,500.00
JS Genetics, Inc. X Chromosome Abnormality Test-Fragil X (XCAT-FX) $ 22,480.53 $ 118,702.53
JS Genetics, Inc. X Chromosomal Abnormality Test-Turner Syndrome Test (XCAT-TS) $ 101,275.94 $ 60,182.91
JS Genetics, Inc. Novel Therapeutic for Priventricular White Matter (Brain White Matter) Injury PWMI $ 30,157.94 $ 134,739.08
Life Recovery Systems HD, LLC The ThermoSuit System $ 194,228.80 $ 50,250.45
Linkwireless LLC RXManager   $ 34,500.00
Lux Biosciences Inc LX214-Voclosporin as a topical solution for the treatment of dry eye syndrome. $ 244,479.24  
Lux Biosciences Inc LX211-Voclosporin for the treatment of Non-infectious Uveitis $ 244,479.25  
Lux Biosciences, Inc. LX212  Treatment of severe dry eye syndrome with a voclosporin implant $ 219,361.50 $ 25,117.75
MEDASYS INCORPORATED PROMETRA II MRI SAFE PROGRAMMABLE DRUG INFUSION PUMP $ 244,479.24  
Medasys Incorporated Prometra Programmable Drug Infusion System $ 244,479.24  
Medical Nutrition USA, Inc Katz Study $ 23,791.50 $ 18,627.45
Medical Nutrition USA, Inc EVANS STUDY $ 64,698.04 $ 64,698.04
Med-In-Touch LLC Health E-Dose Medication Adherence System for Improved Outcomes and Reducing Costs $ 185,000.00 $ 59,479.24
MicroDose Therapeutx Inc MUDI-Multi Use Dry Powder Inhaler $ 244,479.25  
MicroDose Therapeutx, Inc MDT-637 - Respiratory Syncytial Virus (RSV) $ 244,479.24  
MicroDose Therapeutx, Inc. MDT-011 - Breath for Life! $ 244,479.25  
MicroDose Therapeutx, Inc. MDT 006 - Treatment for Gastrointestinal Diseases $ 244,479.25  
Moerae Matrix, Inc. Pre-Clinical Development of Novel Peptide Therapeutics   $ 244,479.25
Monosol Rx, LLC Fast Dissolving Film Drug Delivery $ 244,479.24  
Monosol Rx, LLC Nanoparticle Technology-Insulin Film Delivery $ 51,449.00 $ 193,030.24
MONOSOL RX, LLC SUBLINGUAL AND BUCCAL FILM DRUG DELIVERY $ 244,479.24  
Nephrogenex Inc. Pyridorin Clinical Trials $ 244,479.25  
Neurologix, Inc NLX-P101 $ 244,479.24  
Neurotez Inc. Leptin as a Therapy for Alzheimer's disease $ 244,479.24  
Niiki Pharma, Inc. NKP-46 $ 244,479.24  
Niiki Pharma, Inc. NKP-1339 $ 244,479.24  
NovaDel Pharma Inc Duromist--Sildenafil Oral Spray for the treatment of Erectile Dysfunction   $ 244,479.24
NPS Pharmaceuticals Inc Teduglutide $ 244,479.24  
NPS Pharmaceuticals, Inc NPSP558 $ 244,479.24  
Nymox Corporation NX-1207 for the Treatment of Benign Prostatic Hyperplasia   $ 244,479.25
Oceana Therapeutics Inc Solesta: novel product to treat fecal incontinence $ 244,479.24  
Omthera Pharmaceuticals, Inc Epanova $ 182,843.50 $ 61,635.75
Oncobiologics,  Inc Novel immuno-oncology biopharmaceutical drug development for treatment of cancer $ 125,000.00 $ 119,479.25
Ophthotech Corporation Volociximab $ 244,479.24  
Ophthotech Corporation E10030 $ 244,479.24  
Ophthotech Corporation ARC1905 $ 244,479.24  
Orphan Therapeutics, LLC Lucassin (terlipressin) for Hepatorenal Syndrome (HRS) Type 1 $ 244,479.25  
ORTHOBOND CORPORATION ANTI-MICROBIAL SURFACES FOR IMPLANTABLE MEDICAL DEVICES   $ 244,479.25
ORTHOBOND CORPORATION OSTEOCONDUCTIVE SURFACES FOR IMPLANTABLE MEDICAL DEVICES $ 202,421.64 $ 42,057.61
Orthogen, LLC Improved Cost Effective Dental and Orthopaedic Bone Grafts   $ 123,479.24
PALATIN TECHNOLOGIES, INC MELANOCORTIN AGONIST FOR OBESITY AND RELATED METABOLIC SYNDROME $ 244,479.25  
PALATIN TECHNOLOGIES, INC Melanocortin Agonists for Sexual Dysfunction $ 244,479.25  
PALATIN TECHNOLOGIES INC PL-3994 NATRIURETIC PEPTIDE MMETIC FOR ACUTE ASTHMA $ 113,330.00 $ 131,149.25
PALATIN TECHNOLOGIES, INC Subcutaneous Natriuretic Peptide Mimetic for Cardiovascular Disease $ 244,479.25  
Panoptica inc PAN-90716-DES $ 85,755.50 $ 158,723.75
Panoptica Inc PAN-90806 $ 104,577.00 $ 139,902.25
Panoptica Inc PAN-90716-2 $ 85,755.50 $ 158,723.75
Pestka Biomedical Laboratories, Inc. Synferon $ 191,859.59 $ 52,619.66
Pestka Biomedical Laboratories, Inc. Human Interferon Beta Elisa Kit $ 180,733.27 $ 63,745.98
Pharmalead Therapeutics Inc Breast Cancer Drug   $ 42,500.00
PharmaSeq, Inc Use of Silver Nanostructures on Mirotransponders in Ultra-sensitive Assay $ 48,727.56 $ 95,142.25
PharmaSeq, Inc Microtransponder-based Prostate Cancer Multiplex Assay $ 61,475.69  
PharmaSeq, Inc Cystic Fibrosis DNA-based Assay on Microtransponders $ 244,479.25  
Pharmasset, Inc PSI-7977 $ 244,479.25  
Pharmasset, Inc. PSI-938 and PSI-661 $ 244,479.25  
Pharmos Corporation Dextofisopam to treat Irritable Bowel Syndrome $ 244,479.24  
Phytomedics, Inc. PMI-001 for Treatment of Rheumatoid Arthritis (RA) $ 244,479.25  
Piasek Biotech, Inc Innovative therapy for nasal allegies and related discorders $ 74,340.01 $ 169,439.50
ProFACT Proteomics Inc SeraFILE {TM}: Conformational Variants {Conformers} for Drug and Biomarker Discovery $ 61,831.50 $ 120,260.50
Prolong Pharmaceuticals, LLC Sanguinate - A broad based Oxygen Therapeutic $ 244,479.25  
Prosidyan, Inc. FIRBERGRAFT Anti-mircobial, Ultra-porous, Bioactive, Osteostimulative, bone graft substitute $ 119,005.00 $ 125,474.25
PROVID PHARMACEUTICALS, INC Development of PV-267 A DR2 inhibitor for the treatment of Multiple Sclerosis $ 6,696.50 $ 159,000.00
PTC Therapeutics Inc Development of small molecules to treat spinal mucular atrophy via modulation of $ 62,136.00 $ 18,224.50
PTC Therapeutics Inc Novel Broad Spectrum Antibacterials $ 244,479.25  
PTC Therapeutics Inc Development of small molecules to treat spinal muscular atrophy via modulation of alternative splicing $ 244,479.24  
PTC Therapeutics Inc Discovery & Development of Novel Small Molecule Antiviral Agents against Hepatitis C $ 244,479.25  
PTC Therapeutics Inc Upregulation of the muscle specific form of insulin like growth factor (mlGF-1) to treat muscular dystrophies $ 219,521.50  
PTC Therapeutics, Inc Identification of Compounds that Increase Utrophin Protein to delay progression of DBMD $ 219,521.50 $ 24,957.75
PTC Therapeutics, Inc Inhibition of Myostatin to slow the Progression of Muscular Dystrophies $ 219,521.50  
PTC Therapeutics, Inc. Discovery & Development of Small Molecules that Increase the Translation of Tumor $ 162,655.00 $ 81,824.24
PTC Therapeutics, Inc. Development of Ataluren as a Treatment for Nonsense Mutation Genetic Disorders $ 244,479.25  
PTC Therapeutics, Inc. Development of a Novel Glioblastoma treatment that selectively reduces Bmi-1 $ 206,480.50 $ 37,998.75
PTC Therapeutics, Inc. Development of PTC299 as a Treatment for Cancer and other Neoplastic Conditions $ 244,479.25  
PTC Therapeutics, Inc. Development of small molecules to treat spinal muscular atrophy by a novel $ 45,110.00 $ 17,140.50
QRS Systems, Inc Implantable Heart Monitor and Telemetry Reporting System $ 244,479.24  
QrxPharma Inc TorsinA Activators for Disease Modifying Activity in Protein Misfolding Diseases $ 244,479.24  
QRxPharma, Inc MoxDuo CR- a controlled release oral treatment for moderate to severe chronic pain. $ 244,479.24  
QRxPharma, Inc MoxDuo IR-an immediate release oral treatment for moderate to severe acute pain. $ 244,479.24  
REDPOINT BIO CORPORATION ORAL DRUGS REGULATING INSULIN & INCRETIN SECRETION FOR DIABETES TREATMENT $ 244,479.25  
Regado Biosciences, Inc.  REG2 $ 244,479.24  
Regado Biosciences, Inc. REG3 $ 244,479.24  
Regado Biosciences,Inc. REG1 $ 244,479.24  
Replication Medical Inc. GelStix $ 244,479.25  
Samos Pharmaceuticals LLC Oral and Parenteral Multi-day Delivery of Drugs $ 53,230.00 $ 108,543.00
Savient Pharmaceuticals, Inc Pegloticase $ 244,479.24  
Scivanta Medical Corporation Development of a Minimally-invasive Cardiac Monitor $ 112,500.00 $ 131,979.25
Secant Therapeutics, Inc. Percutaneous Transcatheter Direct Plication Annuloplasty (DPA)   $ 58,500.00
Semorex Incorporated Targeted Intracellular Photodynamic Therapy (TIP) $ 244,479.24  
Senesco Technologies, Inc Use of SNSO1-T as a Therapeutic for Multiple Myeloma $ 244,479.24  
Signum Biosciences Inc Development of Novel Therapeutics for Acne $ 188,551.00 $ 55,928.24
Signum Biosciences, Inc Development of Novel Therapeutics for Alzheimer's Disease $ 244,479.24  
Signum Biosciences, Inc Development of Novel Therapeutics for Rosacea $ 182,012.50 $ 62,466.74
SIGNUM BIOSCIENCES, INC. Development of Novel Therapeutics for Parkinson's Disease $ 244,479.24  
Simon Wiiliams Pharma Consulting LLC VaccJect drug delivery sytem   $ 244,479.25
Soligenix,Inc. (formerly known as DOR BioPharma, Inc.) orBec (oral BDP) for the Treatment/Prevention of Acute Graft-versus-Host Disease (GVHD) $ 244,479.25  
SOMNUS THERAPEUTICS, INC. SKP-1041 CLINICAL TRIALS $ 244,479.25  
SVELTE MEDICAL SYSTEMS, INC Stent on a wire delivery system $ 244,479.25  
TAXIS Pharmaceuticals, Inc. Novel Antibiotic Drug Development - Unique Mechanism of Action to Overcome Resistance $ 106,853.50 $ 137,625.74
Thymon LLC Synthetic HIV-1 Tat epitope vaccine $ 127,606.50 $ 116,872.74
Transave Inc Arikace Cystic Fibrosis (CF) Program $ 244,479.24  
Transave Inc Arikace Nontuberculous Mycobacteria (NTM) Program   $ 244,479.24
Transave Inc Arikace Non-CF Bronchiectasis Program $ 244,479.24  
TRIM-edicine, Inc. Treatment of muscular dystrophy by protein therapeutics. $ 244,479.25  
Tyrx Pharma, Inc ASTRA Antibacterial il for Soft Tissue ReINFORCEMENT AND Infection Control $ 244,479.24  
Tyrx Pharma, Inc. AIGIS Product Family Antibacterial Mesh for Infection Control in Cardiac Rhythn devices $ 244,479.24  
Unigene Laboratories Inc ANNEXIN $ 244,479.25  
Unigene Laboratories, Inc ORAL  PTH $ 244,479.25  
Unigene Laboratories, Inc SITE-DIRECTED BONE GROWTH (SPBG) $ 188,972.00 $ 55,507.25
Unigene Laboratories, Inc SATIETY $ 232,812.50 $ 11,666.75
UROVALVE, INC Surinate Bladder Management System $ 244,479.25  
Valeritas Inc V-GoTM Disposable Insulin Delivery Device $ 244,479.25  
VASCULAR DEVICES LLC RESEAL Vascular Access Graft for Early Access Hemodialysis - For chronoc kidney disese $ 243,000.00 $ 1,479.24
Vascular Therapies, LLC Coll-R Collagen Rapamycin Matrix Project $ 244,479.25  
Vaxinnate Corporation Novel Vaccine Technology for Influenza $ 244,479.24  
VectraCor, Inc. VectraplexPDA Holter System $ 140,925.67 $ 103,553.57
Venenum Biodesign, LLC Venenum CIP2A Development and high throughput screening of an assay designed to isolate. Development and high throughout screening of an assay designed to isolate small molecules blocking C-Myc binding to cancerous inhibitor of protein phosphatase 2A (CIP $ 102,851.50 $ 141,627.75
Venenum Biodesign, LLc Venenum SIRNA: The corresponding proteins expressed by the cancer genes isolated…The isolation of novel biomarkers and cancer drug targets through high throughput SiRNA screening for genes required for cancer cell viability. $ 99,135.50 $ 145,343.75
Vicus Therapeutics LLC VT-122 Development Program $ 192,251.49 $ 52,227.76
VYTERIS, INC. Lutrepatch™ $ 244,479.25  
VYTERIS, INC. Glucagon-like peptide 1 (GLP-1) $ 244,479.25  
WellGen, Inc Using nutrigenomics discovery tools for novel medical foods to treat chronic disease $ 244,479.24  
XEME Biopharma Inc Therapeutic Cancer Vaccines $ 48,313.00  
ZBV II LLC Phase III Trial of Myocet Tratuzumab (T) and Paclitaxel(P) vs T&P for 1st Line HER2+MBC $ 244,479.25  

Rate the Small Business and Self-Employed Website

Page Last Reviewed or Updated: 17-Oct-2014